Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
about
Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in MiceLiposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in MiceDetectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Exogenous endothelial cells as accelerators of hematopoietic reconstitution.Cellular therapy following allogeneic stem-cell transplantation.Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewThe addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Recent advances in the design of drug-loaded polymeric implants for the treatment of solid tumors.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.
P2860
Q33831349-CBE760B4-680A-4AB3-9BFD-884E46DA4466Q33924570-A8D6896D-D826-47E8-86DC-F6C5FD6EC3C4Q33937843-B01965F0-C8F5-461B-AE97-A1090A09535DQ34109670-88187103-EE99-45F6-80DF-528520EE8AFAQ34634251-8877762C-D1AC-475B-8FFC-D7EE6B85C8D4Q34645259-1CBA6FCE-99F2-4BD0-967E-D5FD6E72DECCQ35100974-29A89E57-143C-4F54-83B4-AC78DA3A8CAFQ35747708-5FA3609B-EE31-420A-8A51-0ABE1F2164AEQ35949248-C53007C8-641C-4083-9026-7B6510270264Q36100435-C9463447-976A-4FC2-BF0F-A143D04D8E70Q36527110-2BA59DAF-DD3A-4FA5-B217-8923B4F19F2DQ36612643-8A54EC35-EE68-44DA-B9B1-C4EE07F72BF6Q37148120-56E6600B-CEF4-48F8-98F5-043162B3F25FQ37233236-0E4B966E-17B1-4370-9514-4AEDBBB462ADQ37670062-A8D15BF0-715F-4BC5-99DB-3EFE42F875C1Q37908136-45F59911-2A51-4972-8B6D-C673E2A7A6C0Q38079288-88415999-DAE6-443F-84E5-C157977CC7E3Q38220573-89F224E8-C680-4565-83CF-F86E369FBF32Q38767030-B0BF6607-85B4-413F-9BED-229136370CF2Q47614484-47D4664C-509E-4F35-85DC-D8182E5F3278Q53629618-49EF8B91-20A7-45E8-A42E-B9EA95819E98
P2860
Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Allogeneic transplantation for ...... s aimed at preventing relapse.
@en
Allogeneic transplantation for ...... s aimed at preventing relapse.
@nl
type
label
Allogeneic transplantation for ...... s aimed at preventing relapse.
@en
Allogeneic transplantation for ...... s aimed at preventing relapse.
@nl
prefLabel
Allogeneic transplantation for ...... s aimed at preventing relapse.
@en
Allogeneic transplantation for ...... s aimed at preventing relapse.
@nl
P2093
P1476
Allogeneic transplantation for ...... s aimed at preventing relapse.
@en
P2093
Laurence J N Cooper
Michael A Pulsipher
Peter Bader
P356
10.1016/J.BBMT.2008.11.009
P433
P577
2009-01-01T00:00:00Z